190 related articles for article (PubMed ID: 33721669)
1. Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances.
Dhokne P; Sakla AP; Shankaraiah N
Eur J Med Chem; 2021 Apr; 216():113334. PubMed ID: 33721669
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH
Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307
[TBL] [Abstract][Full Text] [Related]
3. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.
Matheson CJ; Casalvieri KA; Backos DS; Minhajuddin M; Jordan CT; Reigan P
Eur J Med Chem; 2020 Jul; 197():112316. PubMed ID: 32334266
[TBL] [Abstract][Full Text] [Related]
4. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
Kaur M; Singh P
Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310
[TBL] [Abstract][Full Text] [Related]
5. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
6. Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.
Sestito S; Bacci A; Chiarugi S; Runfola M; Gado F; Margheritis E; Gul S; Riveiro ME; Vazquez R; Huguet S; Manera C; Rezai K; Garau G; Rapposelli S
Eur J Med Chem; 2021 Dec; 226():113895. PubMed ID: 34624821
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
Gicquel M; Gomez C; Garcia Alvarez MC; Pamlard O; Guérineau V; Jacquet E; Bignon J; Voituriez A; Marinetti A
J Med Chem; 2018 Oct; 61(20):9386-9392. PubMed ID: 30221935
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of 2-indolinone derivatives as PAK1 inhibitors in MDA-MB-231 cells.
Yao D; Ruhan A; Jiang J; Huang J; Wang J; Han W
Bioorg Med Chem Lett; 2020 Sep; 30(17):127355. PubMed ID: 32738980
[TBL] [Abstract][Full Text] [Related]
9. Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.
Jia CC; Chen W; Feng ZL; Liu ZP
Future Med Chem; 2021 Jan; 13(1):45-62. PubMed ID: 33242992
[No Abstract] [Full Text] [Related]
10. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors.
Lozinskaya NA; Babkov DA; Zaryanova EV; Bezsonova EN; Efremov AM; Tsymlyakov MD; Anikina LV; Zakharyascheva OY; Borisov AV; Perfilova VN; Tyurenkov IN; Proskurnina MV; Spasov AA
Bioorg Med Chem; 2019 May; 27(9):1804-1817. PubMed ID: 30902399
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents.
Chen G; Weng Q; Fu L; Wang Z; Yu P; Liu Z; Li X; Zhang H; Liang G
Bioorg Med Chem; 2014 Dec; 22(24):6953-60. PubMed ID: 25456085
[TBL] [Abstract][Full Text] [Related]
12. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
13. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
[TBL] [Abstract][Full Text] [Related]
14. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.
Sestito S; Nesi G; Daniele S; Martelli A; Digiacomo M; Borghini A; Pietra D; Calderone V; Lapucci A; Falasca M; Parrella P; Notarangelo A; Breschi MC; Macchia M; Martini C; Rapposelli S
Eur J Med Chem; 2015 Nov; 105():274-88. PubMed ID: 26498573
[TBL] [Abstract][Full Text] [Related]
16. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
17. Structure-based pharmacophore models to probe anticancer activity of inhibitors of protein kinase B-beta (PKB β).
Akhtar N; Jabeen I; Jalal N; Antilla J
Chem Biol Drug Des; 2019 Mar; 93(3):325-336. PubMed ID: 30354009
[TBL] [Abstract][Full Text] [Related]
18. Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow.
Fradera X; Methot JL; Achab A; Christopher M; Altman MD; Zhou H; McGowan MA; Kattar SD; Wilson K; Garcia Y; Augustin MA; Lesburg CA; Shah S; Goldenblatt P; Katz JD
Bioorg Med Chem Lett; 2019 Sep; 29(18):2575-2580. PubMed ID: 31416665
[TBL] [Abstract][Full Text] [Related]
19. Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling.
Zhang H; He F; Gao G; Lu S; Wei Q; Hu H; Wu Z; Fang M; Wang X
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770611
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.
Asquith CRM; East MP; Laitinen T; Alamillo-Ferrer C; Hartikainen E; Wells CI; Axtman AD; Drewry DH; Tizzard GJ; Poso A; Willson TM; Johnson GL
Eur J Med Chem; 2024 May; 271():116357. PubMed ID: 38636130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
